Physician profile
David J Kyle
NPI 1952531758
$4,005.13
in general payments reported to CMS, 2019-2025
31 companies · $61.89 in 2025
The $61.89 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.23 · 2021: $422 · 2022: $517 · 2023: $2,119 · 2024: $866 · 2025: $61.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,046.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,742.15 | 2023 | Xeomin |
| Lilly USA, LLC | $431.74 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $205.53 | 2023-2024 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $196.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.20 | 2021-2023 | Jardiance |
| Abbvie INC. | $124.68 | 2023-2025 | |
| Pfizer INC. | $114.30 | 2023-2024 | |
| Becton, Dickinson and Company | $102.99 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $99.34 | 2022-2023 | |
| Novo Nordisk INC | $93.77 | 2019-2024 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $91.92 | 2021 | |
| Revance Therapeutics, INC. | $88.71 | 2024 | Daxxify |
| Astrazeneca Pharmaceuticals LP | $87.06 | 2021-2023 | Breztri |
| Scilex Pharmaceuticals INC. | $86.40 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $36.67 | 2021-2024 | Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $34.04 | 2024 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $33.40 | 2022-2023 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.33 | 2022-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $29.38 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.21 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $23.42 | 2024 | Voquezna |
| Redhill Biopharma INC. | $23.31 | 2022 | |
| Merck Sharp & Dohme LLC | $22.21 | 2021 | |
| Exact Sciences Corporation | $20.69 | 2024 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $19.54 | 2022 | |
| Qiagen, LLC | $18.63 | 2024 | |
| Amgen INC. | $17.90 | 2025 | Repatha, Otezla |
| Nevro Corp. | $17.17 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $14.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.14 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.